More recently, however, newly approved treatments have included edaravone (Edaravone MCI-186 ALS 19 Study Group, 2017), AMX0035 (sodium phenylbutyrate and taurursodiol) (Paganoni et al., 2020) and tofersen (for patients carrying SOD1 mutations) (Miller T. M. et al., 2022). This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.